Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07421700 · ClinicalTrials.gov registry record · Phase 1
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Phase 1 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT07421700 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 132 participants.
The verdict
NCT07421700, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone. * Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin. Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable. Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer. If the cancer gets worse but the treatment is still helping and side effects are manageable, participants may be allowed to continue treatment with their doctor's and the sponsor's agreement.
Interventions
- BIOLOGICAL PF-08634404
- BIOLOGICAL Enfortumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2028-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07421700
The ClinicalTrials.gov registry entry for NCT07421700 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-08634404 is the first listed.
NCT07421700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07421700 about?
NCT07421700 is a clinical study titled "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer". This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to...
What is the current status of trial NCT07421700?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2026-03-11. Estimated completion is 2028-09-05.
What interventions are being tested in trial NCT07421700?
The interventions under investigation include: PF-08634404 (BIOLOGICAL), Enfortumab Vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT07421700?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.